

Incidence of first cardiovascular event in Spanish patients with inflammatory rheumatic diseases: prospective data from the CARMA Project

M.A. Martín-Martínez¹, S. Castañeda², C. González-Juanatey³, F. Sánchez-Alonso¹, C. García-Gómez⁴, R. López-González⁵, J. Babío-Herraiz⁶, A. Juan-Mas⁷, M.P. Moreno-Gil⁸, C.O. Sánchez-González⁹, M. Romera-Baurés¹⁰, J.A. Pinto-Tasende¹¹, J. Tornero-Molina¹², D. Fábregas-Canales¹³, J. Llorca¹⁴, M.A. González-Gay¹⁵⁻¹⁷,
on behalf of the CARMA Project Collaborative Group

¹Research Unit of Spanish Society of Rheumatology, Madrid; ²Division of Rheumatology, Hospital Universitario de la Princesa, IIS-Princesa, Madrid; ³Division of Cardiology, Hospital Lucus Augusti, Lugo; ⁴Division of Rheumatology, Consorci Sanitari de Terrassa, Barcelona; ⁵Division of Rheumatology, Hospital General Virgen de la Concha, Zamora; ⁶Division of Rheumatology, Hospital de Cabueñes, Gijón; ⁷Division of Rheumatology, Hospital Son Llatzer, Palma de Mallorca; ⁸Division of Rheumatology, Hospital San Pedro de Alcántara, Cáceres; ⁹Division of Rheumatology, Hospital del Sureste, Madrid; ¹⁰Division of Rheumatology, Hospital de Bellvitge, Barcelona; ¹¹Division of Rheumatology, Complejo Hospitalario A Coruña, Xubias de Arriba, A Coruña; ¹²Division of Rheumatology, Hospital Universitario de Guadalajara; ¹³Division of Rheumatology, Hospital de Barbastro, Huesca; ¹⁴Division of Epidemiology and Computational Biology, School of Medicine, University of Cantabria and CIBER Epidemiología y Salud Pública (CIBERESP); Santander; ¹⁵Division of Rheumatology, University of Cantabria, Hospital Universitario Marqués de Valdecilla, Santander; ¹⁶Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, IDIVAL, Santander, Spain; ¹⁷University of the Witwatersrand, Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, South Africa.

Abstract Objective

To determine the incidence and risk factors of first cardiovascular event (CVE) in patients with chronic inflammatory rheumatic diseases (CIRD).

Methods

Analysis of data after 2.5 years of follow-up from the prospective study CARMA project, that includes patients with CIRD [rheumatoid arthritis (RA), ankylosing spondylitis (AS), and psoriatic arthritis (PsA)] and matched individuals without CIRD from 67 hospitals in Spain. CVE cumulative incidence per 1000 patients was calculated after 2.5 years from the start of the project. Weibull proportional hazard model was used to calculate hazard ratio (HR) and 95% confidence interval (95% CI) of the risk factors.

Results

2595 (89.1%) patients completed the 2.5 years of follow-up visit. Cumulative incidence of CVE in patients with CIRD was 15.30 cases per 1000 patients (95% CI: 12.93–17.67), being higher in the subgroup with AS; 22.03 (95% CI: 11.01–33.04). Patients with AS (HR: 4.11; 95% CI: 1.07–15.79), those with older age (HR: 1.09; 95% CI: 1.05–1.13), systolic hypertension (HR: 1.02; 95% CI: 1.00–1.04) and long duration of the disease (HR: 1.07; 95% CI: 1.03–1.12) were at higher risk of first CVE during the 2.5 years of follow-up. In contrast, female gender was a protective factor (HR: 0.43; 95% CI: 0.18–1.00).

Conclusion

Among CIRD patients prospectively followed-up at rheumatology outpatient clinics, those with AS show higher risk of first CVE. Besides cardiovascular risk factors, such as hypertension, being a man and older as well as having a long disease duration increase the risk of CVE in patients with CIRD.

Key words

incidence, cardiovascular diseases, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, cohort study, CARMA project

María A. Martín-Martínez, MD
Santos Castañeda, MD, PhD
Carlos González-Juanatey, MD, PhD
Fernando Sánchez-Alonso, MD
Carmen García-Gómez, MD, PhD
Ruth López-González, MD, PhD
Jesús Babío-Herraiz, MD
Antonio Juan-Mas, MD, PhD
María P. Moreno-Gil, MD
Carmen O. Sánchez-González, MD
Montserrat Romera-Baurés, MD, PhD
José A. Pinto-Tasende, MD, PhD
Jesús Tornero-Molina, MD, PhD
Dolores Fábregas-Canales, MD
Javier Llorca, MD, PhD
Miguel A. González-Gay, MD, PhD

The members of the CARMA Project Collaborative Group are listed on page 737.

Please address correspondence to:
Prof. Miguel A. González-Gay,
Rheumatology Division, Hospital
Universitario Marqués de Valdecilla,
IDIVAL, Avenida de Valdecilla, s/n,
39008 Santander, Spain.
E-mail: miguelaggay@hotmail.com

Received on August 1, 2018; accepted in revised form on November 5, 2018.

© Copyright CLINICAL AND
EXPERIMENTAL RHEUMATOLOGY 2019.

Funding: this project was supported by an unrestricted grant from Abbvie, Spain. However, the design, analysis, interpretation of results and preparation of the manuscript was made independently of Abbvie.

Prof. González-Gay's research was supported by grants from "Fondo de Investigación Sanitaria" (grants PI06/0024, PS09/00748, PI12/00060 and PI15/00525) from 'Instituto de Salud Carlos III' (ISCIII, Health Ministry, Spain) and by RETICS Programs RD12/0009 and RD16/0012 (RIER) from 'Instituto de Salud Carlos III' (ISCIII, Health Ministry, Spain),

Competing interests: S. Castañeda received consultation fees/participation in company sponsored speaker's bureau from Amgen, BMS, Lilly, MSD, Pfizer, Roche and Sobi; M.A. González-Gay received grants/research support from Abbott, MSD, Janssen and Roche, and had consultation fees/participation in company sponsored speaker's bureau from Abbott, Lilly, MSD, Novartis, Pfizer, Roche, Sanofi and Sobi; the other authors have declared no competing interests.

Introduction

Cardiovascular (CV) disease (CVD) is more common in patients with chronic inflammatory rheumatic diseases (CIRD) than in the general population (1). This increased CVD risk results from the effect of traditional CV risk factors (CVRFs) along with chronic inflammation and a genetic component (2-4), leading to a process of accelerated atherogenesis (5, 6). Different reports highlight the complex interaction of classic CVRFs with chronic inflammation and certain genetic components (7-10).

In patients with rheumatoid arthritis (RA), the incidence of CV events (CVE) is augmented by almost 50% compared to the general population, while the risk of myocardial infarction (MI) and stroke is increased by about 68% and 41%, respectively (1, 4). As observed in patients with type 2 diabetes, different studies have shown a higher incidence of CV mortality in RA patients compared to people of the same age and sex (11-13). In general, patients with RA have a 2 to 3-fold increased risk of MI, even in the absence of traditional CVRFs (8, 14-16). An increased prevalence of ischaemic heart disease (IHD) in patients with RA was found in a recent study that included 11,782 patients with RA and 57,973 age and sex matched controls, (16.6% versus 12.8% respectively, $p < 0.001$) (17). Spondyloarthropathies (SpA) constitute another group of CIRD associated with a higher CVD risk than the general population (18, 19). In this regard, CVE and CV mortality are more common in patients with psoriatic arthritis (PsA) than in the general population regardless of the presence of classic CVRFs (20-22). The presence of severe psoriasis was found to be an important predictor for the development of CVE in these patients (21, 22). PsA patients without traditional CVD risk factors also have higher frequency of subclinical atherosclerosis than matched controls (23, 24). Therefore, although the role of classic CVRFs cannot be ruled out (20), the disease itself appears to be a good predictor of CVE. Ankylosing spondylitis (AS) has also been associated with a mortality rate 1.5 to 2.0 times greater

than the general population, which is largely due to CVD complications (18, 25, 26).

Despite these evidences, most epidemiological studies on CVD in CIRD have methodological limitations, mainly due to their retrospective nature. Because of that, we analysed the incidence of CVE in patients from the prospective CARdiovascular in rheumatology (CARMA) project that included patients with CIRD attending Spanish rheumatology clinics after a first assessment performed at 2.5 years of follow-up.

Patients and methods

Study design

The CARMA project is a prospective cohort study aimed to identify the CVD risk profile in patients with CIRD after 10 years of follow-up. It includes patients with RA, AS and PsA as well as a cohort of patients without inflammatory disease, who have been recruited in 67 Spanish hospitals (27). In this report, we describe the results at 2.5 years of follow-up.

Study population

As previously reported (27), patients with CIRD and individuals without CIRD attending outpatient rheumatology clinics from the participating hospitals were invited to take part in the study. The period of recruitment was July 2010 to January 2012.

A probabilistic cluster sampling that ensured that the different Rheumatology Units (RU) in Spain had equal probabilities of being chosen was performed. We randomly selected 67 Spanish centres with RU from the database of the Spanish Society of Rheumatology (SSR). Recruitment was done by the inclusion of consecutive patients with any of the three aforementioned conditions, regardless of disease severity or duration. The recruited patients fulfilled one of the following inclusion criteria: the 1987 American College of Rheumatology (ACR) Classification Criteria for RA (28), the modified New York Criteria for Definite AS (29), or the Moll and Wright Criteria for PsA (30). The selection of the controls was performed at the rheumatology outpatient's clin-

ics where the patients with inflammatory arthritis, RA, AS and PsA, were recruited. Controls were selected during the same period of recruitment as patients did. The criteria for the selection of controls were the following: individuals aged 18 years and older attending rheumatology outpatient's clinics for conditions different from inflammatory arthritis, connective tissue diseases or systemic vasculitis. Because of that, individuals with osteoarthritis, osteoporosis and those with mechanic low back pain and soft tissue rheumatisms (*e.g.* epicondylitis, trochanteric bursitis, anserine bursitis) were included as controls. However, subjects with erosive (inflammatory) osteoarthritis of the hands or with microcrystalline arthropathies were not eligible as controls. Patients and controls were matched by age (± 5 years) and sex at ratio of 1:1. Moreover, we performed a multivariate statistical analysis to control the possible bias that could have occurred as the result of the heterogeneous distribution of potential confounding factors in both cohorts. The recruitment of all the subjects included in this study, both individuals with inflammatory arthritis (RA, AS and PsA) and controls was performed following the date in which they attended the rheumatology outpatient clinic of each centre, regardless of their severity or the duration of their disease. At the end of the recruitment period, 2986 patients who had met the inclusion criteria were invited to participate. Of them, 75 declined to take part in the study. The statistical power was estimated using the remaining 2911 patients (775 RA, 738 AS, 721 PsA, and 677 non-CIRD individuals). The percentage of individuals with high or very high CV risk according the European Systematic COronary Risk Evaluation (SCORE) risk charts, which identify these patients if values are $\geq 5\%$, was 6% in the controls and 12% in the RA cohort (31, 32). Based on this assumption, the power of the sample numbering 2911 individuals to detect a statistically significant risk difference of 6% between the cohorts was 0.98. From the initial series of 2911, 2595 of them (89.1%) accomplished the 2.5 years follow-up visit.

Follow-up

Patients included in the study were actively followed-up by their rheumatologists in an attempt to identify the occurrence of the first CVE. The follow-up was considered successful if the patient fulfilled the 2.5-year follow-up visit, had suffered his/her first CVE within the 2.5 years follow-up period or had died by CV cause. Otherwise, the patient was considered lost to follow-up. When a patient was lost to follow-up, researchers in the participant hospitals looked for a possible cause of death at the hospital and primary care centre medical records. They also searched for information on fatal or a non-fatal CV disease events from other centres of the Spanish National Health system. In the cases lost to follow-up in whom this information was not available, data provided by the Spanish Statistical Office was assessed to determine if the patient was alive or dead and, in this case, the cause of the death.

Variables and operative definitions

The main variable analysed was the presence of a first CVE (IHD, cerebrovascular accidents [CVA], peripheral arterial disease [PAD], heart failure [HF] and mortality from these causes) from the time of the inclusion in the study to the 2.5 years follow-up visit in patients without previous history of CVD. Secondary variables were as follows: (1) traditional (classic) CVRFs (hypertension, dyslipidaemia, obesity, smoking, and diabetes); (2) parameters of inflammation and disease activity; (3) sociodemographic variables (age and sex), comorbidities and laboratory parameters; and (4) potential confounding factors (disease severity, duration of disease, and therapies). Operative definitions of the principal and secondary variables can be found in the Supplementary material of the article published by Castañeda *et al.* (27). The CVE risk was calculated for people without CVE at the beginning of the CARMA project.

Statistical analysis

Numerical variables with normal distribution were expressed as mean and standard deviations (SD). Variables not normally distributed were expressed as

median and interquartile ranges (IQR p25–p75). Absolute and relative frequencies were calculated for qualitative variables.

A descriptive analysis of losses to follow-up was carried out. Comparison with patients who attended the 2.5 years visit was performed using parametric and nonparametric tests according to the distribution of each variable. Numerical variables were assessed using the Student *t*-test or the Mann-Whitney U-test. Qualitative variables were assessed by a Chi-squared test (with or without Yates correction), or Fisher's exact test in 2x2 tables. Cumulative incidence of the first CVE per 1000 patients along with 95% confidence interval (CI) for the total number of patients and also for each group of conditions was also calculated. Bivariate analysis of the patients who completed the 2.5 years follow-up visit was conducted. Later, a multivariate proportional hazard Weibull model was carried out. Development of first CVE from the entry of the study up to the 2.5 years follow-up visit was the dependent variable. Results were presented as hazard ratio (HR) and 95% CI.

The selection of independent variables in the multivariate models was based on clinical judgments and those with $p < 0.20$ in the bivariate analysis were included. All analyses were performed using the SPSS 21.0 statistical programme. This study was performed following the principles outlined in the Helsinki Declaration, and the study protocol was approved by the Ethics Committee for Clinical Research of Galicia, Spain (approval number: 2009/077). All patients had written informed consent to participate in the study and to publish the data obtained.

Results

Two thousand nine hundred eleven patients were included in the study: 775 patients with RA, 738 with AS, 721 with PsA, and 677 individuals attending rheumatology outpatient clinics without CIRD or autoimmune diseases. Of them, 89.1% (2595: 706 RA, 657 AS, 661 PsA and 571 controls) performed the 2.5 years follow-up visit. Among the patients who attended the 2.5 years

Table I. Baseline sociodemographic, traditional cardiovascular risk factors and clinical characteristics of the population included in the study.

Variables	Rheumatoid arthritis (n=775)	Ankylosing spondylitis (n=738)	Psoriatic arthritis (n=721)	Matched cohort (n=677)	p-value
<i>Sociodemographic features</i>					
Age at inclusion, years, mean (SD)	57.1 (12.3)	48.1 (11.7)	51.8 (12.0)	54.0 (12.4)	<0.001
Age at the beginning of disease, years, mean (SD)	45.8 (13.4)	29.7 (11.8)	39.5 (13.3)	48.5 (12.4)	<0.001
Sex, female, n (%)	581 (75.0)	200 (27.1)	327 (45.4)	437 (64.5)	<0.001
Educational level, n (%)					
- Elementary	467 (60.9)	318 (43.3)	331 (46.3)	229 (34.1)	
- Secondary /University	300 (39.1)	416 (56.7)	383 (53.7)	443 (65.9)	<0.001
<i>Traditional CVRF</i>					
BMI, kg/m ² , mean (SD)	26.9 (4.8)	27.4 (4.4)	28.2 (4.7)	26.7 (4.4)	<0.001
Abdominal perimeter (cm), mean (SD)	93.7 (7.0)	96.3 (12.9)	97.6 (13.0)	93.5 (12.9)	<0.001
Hypertension, n (%)	236 (30.5)	190 (25.7)	213 (29.5)	158 (23.3)	0.008
Hypercholesterolaemia, n (%)	238 (30.7)	199 (27.0)	257 (35.6)	224 (33.1)	0.003
Total cholesterol (mg/dL)	204.2 (35.6)	196.6 (37.0)	202.1 (36.1)	208.7 (39.9)	<0.001
Triglycerides (mg/dL)	107.2 (55.2)	113.2 (71.6)	121.5 (76.8)	110.2 (70.2)	0.001
LDL-c (mg/dL), mean (SD)	122.8 (32.9)	123.6 (32.3)	124.2 (32.0)	128.0 (36.9)	0.023
HDL-C (mg/dL), mean (SD)	61.3 (17.2)	52.8 (13.9)	54.4 (14.9)	59.9 (16.8)	<0.001
Atherogenic index, mean (SD)	3.6 (1.3)	4.0 (1.2)	3.9 (1.1)	3.7 (1.1)	<0.001
Diabetes mellitus, n (%)	60 (7.8)	56 (7.6)	66 (9.2)	34 (5.0)	0.030
Obesity (BMI ≥30), n (%)	180 (23.2)	186 (25.2)	209 (29.1)	147 (21.8)	0.010
Smoking status, n (%)					
- Current smokers	189 (24.4)	254 (34.4)	157 (21.8)	143 (21.2)	
- Past smokers	202 (26.1)	240 (32.5)	227 (31.5)	176 (26.0)	<0.001
- Never smoking	384 (49.5)	244 (33.1)	337 (46.7)	357 (52.8)	
<i>Clinical characteristics</i>					
Disease duration, years	8.0 [3.0-14.0]	15.0 [8.0-26.0]	9.0 [4.0-16.0]	2.0 [0.0-6.0]	<0.001
DAS28-ESR	3.1 [2.3-4.0]	--	2.9 [2.0-3.8]	--	0.002
HAQ (0-3)	0.5 [0.1-1.1]	--	0.4 [0.0-0.9]	--	<0.001
BASDAI, mm (0-10)	--	3.5 [1.7-5.3]	--	--	--
BASFI, mm (0-10)	--	3.1 [1.3-5.2]	--	--	--
ESR, mm/1 st hour	17.0 [9.0-29.0]	10.0 [6.0-21.0]	12.0 [6.0-21.0]	10.0 [5.0-18]	<0.001
CRP, mg/L	3.1 [1.2-8.0]	3.6 [1.6-8.9]	2.9 [1.4-6.1]	1.9 [1.3-3.3]	<0.001
RF positive, n (%)	528 (68.1)	--	--	--	--
ACPA positive, n (%)	482 (62.2)	--	--	--	--
HLA-B27, n (%)	--	561 (76)	--	--	--
Erosions (RA), n (%)	352 (45.4)	--	--	--	--
Biologic DMARDs, n (%)	313 (40.4)	349 (47.4)	300 (41.7)	--	<0.001
Synthetic DMARDs, n (%)	674 (87.0)	239 (32.4)	536 (74.5)	--	<0.001
NSAID, n (%)	309 (39.9)	431 (58.5)	329 (45.9)	142 (21.0)	<0.001
GC, n (%) ever treated	357 (46.1)	59 (8.0)	129 (17.9)	--	<0.001
Statins, n (%)	161 (20.8)	119 (16.1)	156 (21.6)	136 (20.1)	0.04

All variables are recorded at the time of inclusion in the study.

Data expressed as median [IQR] unless specified. Categorical variables are expressed as number (n) and percentages (%); SD: standard deviation. ACPA: anti-cyclic citrullinated peptide antibodies; BASDAI (0-10): Bath Ankylosing Spondylitis (AS) Disease Activity Score; BASFI (0-10): Bath AS Functional Index; BMI: body mass index; CRP: C-reactive protein; CV: cardiovascular; CVRF: cardiovascular risk factors; DAS28-ESR: Disease Activity Score using 28 joints-erythrocyte sedimentation rate; DMARD: Disease-modifying anti-rheumatic drugs; GC: glucocorticoids; HAQ (0-3): Health Assessment Questionnaire; HLA-B27: histocompatibility antigen HLA-B27; NSAID: non-steroidal anti-inflammatory drugs; RA: rheumatoid arthritis; RF: rheumatoid factor.

follow-up visit, 52.9% were women. The mean age (SD) at the onset of the study was 52.3 (12.6) years. The main baseline sociodemographic and clinical characteristics of the patients included in the study are shown in Table I.

Losses to follow-up and their causes

The group of patients that showed the highest loss to follow-up was the group of controls without CIRD patients (15.9%), followed by patients with AS (11.1%), RA (9.2%) and those with PsA (8.6%). The outcome of the patients at

2.5 years of follow-up visit is shown in Supplementary Table S1. There were no significant differences between the group of patients who were lost to follow-up and those who completed the 2.5 years visit, except for hypertension, which was more prevalent in the loss to follow-up patient group (33% vs. 26.7%, $p=0.03$) and smoking habit. Also, the frequency of high CVD risk according to the SCORE at the onset of the study was higher among those who were lost to follow-up (16.4% vs. 12.9%, $p<0.05$). The main sociodemographic

factors and clinical characteristics of the patients who were lost to follow-up are described in Supplementary Table S2.

Cumulative incidence of CVE

During the 2.5 years follow-up time, 51 CIRD patients experienced a first CVE (Table II). Twenty-three of them were due to IHD, 16 CVA, 7 PAD and 5 HF episodes.

At 2.5 years from the onset of the prospective assessment the cumulative incidence of CVE in the individuals without CVE at the time of recruitment was

Table II. Cardiovascular events and cumulative incidence of cardiovascular events in our cohort at the 2.5 years follow-up visit*.

	Total	RA	AS	PsA	Matched controls	p-value
CVE, n	51	11	16	13	11	0.04
CVE Cumulative incidence [95% CI]	15.3 [12.9-17.7]	11.5 [3.1-19.5]	22.03 [11.0-33.0]	16.5 [6.8-26.1]	11.04 [2.9-19.2]	<0.05

RA: rheumatoid arthritis; AS: ankylosing spondylitis; PsA: psoriatic arthritis; CVE: cardiovascular events; n: number; CI: [confidence interval].

*The comparative analysis between the different groups in pairs did not yield statistical differences, showing the following data: RA vs. controls (p -value=0.465), AS vs. controls (p =0.06), PsA vs. control group (p =0.200), RA vs. AS (p =0.064), RA vs. PsA (p =0.219), and AS vs. PsA (p =0.228).

15.3 cases per 1000 patients (95% CI: 12.9–17.7). Patients with AS exhibited the highest cumulative incidence of first CV event (22.03; 95% CI: 11.01–33.04). CVE cumulative incidence in RA, PsA and controls is shown in Table II.

Cardiovascular mortality

Overall, only seven patients had died due to CVE and 30 because of non-CVE between the basal visit and the 2.5 years follow-up time.

Risk factors to develop the first CVE

After excluding those with CVD prior to inclusion in the study, the total number of patients who completed the 2.5 years follow-up visit was 2402 patients. The mean age at the onset of the study of the patients who developed a first CVE was 62.9 (12.02) years and 68.3% were men. Table III shows the main characteristics of the patients who developed a first CVE throughout the 2.5 years of follow-up.

The highest risk of developing a first CVE during the 2.5 years of follow-up was found in those with AS (HR: 4.11; 95% CI: 1.07–15.79, p =0.04), patients with older age (HR: 1.09; 95% CI: 1.05–1.13, p <0.001), higher systolic blood pressure (HR: 1.02; 95% CI: 1.00–1.04, p =0.01) and longer duration of the rheumatic disease (HR: 1.07; 95% CI: 1.03–1.12, p <0.01). In contrast, female gender was a protective factor (HR: 0.43; 95% CI: 0.18–1.00, p =0.05) (Table IV).

Impact of the biologic therapy on CVE

We also aimed to assess the potential impact of receiving biologic drugs (the exposure) on the outcome data. For this purpose, we recalculated the crude and adjusted HR of the effect of biologic therapy, stratifying each one the CIRD

Table III. Baseline features of the patients who developed a first CVE from the inclusion in the study to the 2.5 years follow-up visit.

Variables	Patients who completed the first follow-up visit (2.5 years) (n=2402) [§]		
	With first CVE (n=51)	Without first CVE (n=2351)	p-value
Age, mean (SD)	62.9 (12.02)	52.0 (12.47)	<0.001
Disease duration (years), median [p25-p75]	11.5 [2.7-23.2]	8 [3-16]	0.07
Sex (women), (%)	31.7	54.4	<0.01
Smoking status, (%)			
Current smokers	34.1	46.1	0.14
Past smokers	41.5	28	
Never smoking	24.4	25.9	
SCORE, (%)			
Low	17.1	54.5	<0.001
Moderate	36.6	34.9	
High	46.3	10.6	
Family history of IHD, (%)	4.9	12.4	0.14
Hypercholesterolaemia, (%)	58.8	22.3	<0.001
Hypertension, (%)	41.5	28.8	0.07
Obesity (BMI ≥ 30), (%)	22.5	24.2	0.81
Diabetes mellitus, (%)	4.9	1.3	0.05
Total cholesterol (mg/dl), mean (SD)	206 (38.7)	204.7 (36.3)	0.81
Systolic blood pressure (mmHg), mean (SD)	142.2 (19.8)	129.6 (18)	<0.001
ESR (mm/1 st h), median [p25-p75]	16 [17-27]	12.2 [6-12]	0.14
CRP (mg/l), median [p25-p75]	4.5 [2-9.5]	2.9 [1.1-6.1]	0.03

[§]After excluding those with CVE prior to inclusion in the study. All variables are recorded at the time of inclusion in the study. SD: standard deviation; SCORE: Systematic Coronary Risk Evaluation; CVE: cardiovascular event; IHD: ischaemic heart disease; BMI: body mass index; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein.

included in our cohort separately (RA, AS and PsA) (Table S3). We could not find a significant effect of the biologic therapy on CVE in any of the groups, although the point estimates of HR suggests a protective effect of the biologic therapy reducing the risk of CVE in patients with RA and AS. However, the width of the confidence intervals did not allow us to perform further analyses. Nevertheless, we feel that the relationship between the use of biologic therapy and the development of CVE may be altered by a potential confounding-by-indication bias, as patients with higher disease activity were expected to be treated with biologic DMARDs more commonly and to have higher risk

of suffering CVE due to disease severity as well (Table S3).

Discussion

The present prospective study confirms the claim that CVE are increased in unselected patients with CIRD. In our series, it was mainly due to individuals with AS. A predominance of men and a longer disease duration may have accounted for a higher incidence of CVE in the subgroup of AS than in other CIRD patients. Also, CVRFs, such as hypertension, increased the risk of CVE. In the CARMA study the frequency of hypertension was higher in the subgroup of patients with RA (30.5%). Hypertension was also common in the

Table IV. Risk factors to experience first CVE from the inclusion in the study to the 2.5 years follow-up visit.

Variables	HR (95% CI) Crude	HR (95% CI) Adjusted	p-value
Type of CIRD (ref. patients without CIRD)			
RA	1.01 (0.37-2.78)	1.02 (0.29-3.65)	0.97
AS	1.92 (0.78-4.71)	4.11 (1.07-15.79)	0.04
PsA	1.33 (0.51-3.49)	1.39 (0.38-5.05)	0.61
Age at the onset of the study	1.04 (1.02-1.06)	1.09 (1.05-1.13)	<0.001
Sex (ref. men)	0.41 (0.21-0.79)	0.43 (0.18-1.00)	0.05
Smoking (ref. never smoking)			
Current smokers	1.25 (0.56-2.81)	1.17 (0.45-3.01)	0.75
Past smokers	1.94 (0.95-3.98)	0.93 (0.39-2.19)	0.87
Family history of IHD (ref. no)	0.38 (0.09-1.58)	0.29 (0.04-2.16)	0.23
Diabetes mellitus (ref. no)	3.78 (0.91 - 15.66)	1.64 (0.21-12.94)	0.64
Systolic blood pressure, (mmHg)	1.03 (1.02 - 1.05)	1.02 (1.00-1.04)	0.01
Hypercholesterolaemia (ref. no)	1.68 (0.89 - 3.16)	0.83 (0.39-1.80)	0.64
Disease duration (years)	1.03 (1.00 - 1.05)	1.07 (1.03-1.12)	<0.01
ESR (mm/1 st h)	1.02 (1.00 - 1.03)	1.00 (0.98-1.03)	0.7

All variables are recorded at the time of inclusion in the study.

HR: hazard ratio; CIRD: chronic inflammatory rheumatic diseases; RA: rheumatoid arthritis; AS: ankylosing spondylitis; PsA: psoriatic arthritis; IHD: ischaemic heart disease; ESR: erythrocyte sedimentation rate. HR adjusted for all variables included in the multivariate model.

COMorbidities in Rheumatoid Arthritis (COMORA) study (33). In this international, cross-sectional study, which included 3920 patients with RA from 17 participating countries on five different continents, the frequency of hypertension was 40.4%. However, the prevalence of CVD in RA patients from the COMORA study was lower than that observed in the patients with RA from the CARMA study at the baseline visit (6.6% vs. 10.5%) (27, 33). A possible explanation for this discrepancy may be the different definitions for CVD used in these studies. In this regard, in the COMORA study only myocardial infarction and stroke were included in this category whereas in the CARMA study CVD was defined by the presence of IHD (angina and myocardial infarction), CVA, HF of ischaemic origin and peripheral arteriopathy.

Our results are in keeping with data published by other authors (34,35). With respect to this, in a meta-analysis that encompassed seven longitudinal studies, Mathieu *et al.* described an increased risk of acute myocardial infarction (odds ratio [OR]: 1.60; 95% CI: 1.32–1.93) and CVA (OR: 1.50; 95% CI: 1.39–1.62) in AS when compared to the general population without inflammatory diseases (36). Also, Vinker *et al.* have recently reported a higher

risk of CVE in patients with AS than in the control group (14.1% vs. 6.36%, respectively, $p < 0.01$) (37).

In a meta-analysis of observational studies reported by Avina-Zubieta *et al.* (1), patients with RA had higher risk of developing acute myocardial infarction (68%) and CVA (41%) than the general population. However, in contrast to what might be expected, RA patients from our series did not show a higher increase in the risk of developing CVE after 2.5 years of follow-up when compared to controls without CIRD. Since the EULAR recommendations for CVD risk management in patients with RA have been actively discussed by the members of the Spanish Society of Rheumatology (38, 39), it is possible that the impact of these recommendations along with further recommendations proposed by members of the Spanish Society of Rheumatology (38, 40), including the search for patients with RA at high risk of CVD using non-invasive tools (41–43), may have had a positive influence on the results found in our prospective follow-up study.

RA patients with worse control of disease activity have an increased risk of type 2 diabetes (44). The close association between uncontrolled disease activity in patients with inflammatory arthritis and cardiometabolic comor-

bidity was supported by Ruscitti *et al.* (44). Also, Crepaldi *et al.* (45) have reported that diabetes was associated with higher disease activity. Although patients with chronic inflammatory rheumatic diseases (RA, AS and PsA) from the CARMA study had an acceptable control of the disease, they also had a higher frequency of diabetes than controls. However, in the adjusted multivariate model the difference did not reach statistical significance.

As discussed before, besides classic CVRFs, the duration of disease seems to influence the development of accelerated atherogenesis in CIRD patients (36, 46, 47). Also, the magnitude and chronicity of the inflammatory burden was found to correlate directly with the presence of subclinical atherosclerosis in patients with RA (48). In the present study, a longer duration of the disease was related independently with an increased risk of developing CVE at 2.5 years of the study. Also, baseline ESR and CRP levels were higher in the subgroup of CIRD patients who experienced CVE over the 2.5 follow-up period, although they did not reach statistical significance in the multivariate analysis. Interestingly, in a sample of 1222 patients that was randomly selected from the register of a rheumatology outpatient clinic in Amsterdam (49), the ESR was considered as a predictive factor of CVD mortality in patients with RA. This study also showed that patients with RA had a higher risk of CVD mortality than the general population. This finding was maintained throughout the 15 years of the study.

Our study has a number of strengths and limitations. In this regard, it included a large cohort of patients that encompassed 3 of the most representative chronic inflammatory rheumatic diseases (RA, AS and PsA). This fact allowed us to establish comparisons between the different subtypes of inflammatory arthritis, since we used a common methodology for data collection and patient follow-up. Another strength of the study was the low rate of loss of subjects after 2.5 years of follow-up. Moreover, the prospective design of the study allowed us to verify hypothesis of causality. However, the main limitation

of our study is that the follow-up period of 2.5 years is still short to reach definitive conclusions. Moreover, our study included a population of individuals periodically assessed at rheumatology units. Tight control of these patients may underestimate the actual prevalence of CVD in patients with CIRD.

In summary, despite efforts to improve the management of patients with CIRD, the results from the present study indicate that patients with AS followed-up prospectively in rheumatology outpatient clinics have an increased risk of CVE. Male gender, age, systolic hypertension, and a longer duration of disease, are associated with CVE in patients with CIRD attending rheumatology outpatient's clinics

CARMA Project Collaborative Group

The members of the CARdiovascular in rheuMATology Project Collaborative Group include: Eugenia González de Rabago, Elena Alonso Blanco Morales, J. Carlos Fernández Lopez, Natividad Oreiro Villar, Antonio Atanes Sandoval, Francisco J. Blanco García (Complejo Hospitalario A Coruña, Xubias de Arriba, A Coruña); Cayetano Alegre De Miquel, María J. González Fernández, Ramón Huguet Codina, Beatriz Yoldi, Mercedes Ramentol (Instituto Dexeus, Barcelona); Gabriela Ávila, Sara Marsal Barril, Estefanía Quesada (Hospital Universitari Vall d'Hebron, Barcelona); Martina Steiner, Santiago Muñoz, Tatiana Cobo (Hospital Infanta Sofía, Madrid); Fernando Gamero, José García Torón, (Hospital S. Pedro de Alcántara, Cáceres); Pilar Espino, Inmaculada Ros, Mónica Ibáñez, and Claudia Murillo (Hospital Son Llatzer, Palma de Mallorca); Raimon Sanmartí, Horacio Berman, Sonia Cabrera, and Virginia Ruiz (Hospital Clinic i Provincial, Barcelona); Oscar Fontseré Patón, Benjamín Fernández Gutiérrez, and Lydia Abasolo (Hospital Clínico Univ. San Carlos, Madrid); Jose M. Pina (Hospital de Barbastro, Huesca); Joan M. Nolla (Hospital Univ. de Bellvitge, Barcelona); Miriam García Arias, Jesús A. García Vadillo, and Rosario García de Vicuña (Hospital Univ. De La Princesa, Madrid); Antonio Fernández Nebro, Sara Manrique Arija;

Maria A. Belmonte López, Inmaculada Ureña, María V. Irigoyen, Virginia Coret Cagigal (Hospital Regional Universitario Carlos Haya, Málaga); Daniel Pielfort Garrido, Angel M. García Aparicio, Rebeca Belmonte Gómez, Pastora Granados Bautista, Azucena Hernández Sanz (Hospital Virgen de la Salud, Toledo); Javier Bachiller, (Hospital Ramón y Cajal, Madrid); Francisco J. Manero, Fernando Jiménez Zorzo, Eugenio Giménez Ubeda, Jesús Marzo García, Chesús Beltrán Audera, Marta Medrano, Ángela Pecondón (Hospital Univ. Miguel Servet, Zaragoza); Celia Erausquin, Soledad Ojeda, Juan Carlos Quevedo, Félix Francisco, Carlos Rodríguez Lozano (Hospital Dr. Negrín, Las Palmas de Gran Canaria); Francisco J. López Longo, Delia Gerona, Carlos González Fernández, Indalecio Monteagudo (Hospital Gregorio Marañón, Madrid); Javier del Pino, María Dolores Sánchez González (Hospital Univ. de Salamanca); Alfonso Corrales, María Enriqueta Peiró (Hospital Univ. Marqués de Valdecilla, Santander); José M. Senabre, José C. Rosas (Hospital de la Marina Baixa, Alicante); Isabel Rotés, Estefanía Moreno, Alba Erra, Dolors Grado (Hospital de San Rafael, Barcelona); Javier Calvo, Amalia Rueda (Hospital General. Universitario, Valencia); Ingrid Möller, Isabel Rodríguez (Instituto Poal, Barcelona); Carmen Barbadillo (Hospital Universitario Puerta de Hierro, Madrid); Enrique Raya, Pilar Morales, Ana Nieto, Inmaculada Jiménez, Cesar Magro (Hospital Clínico Univ. San Cecilio, Granada); Ana Ruibal Escribano (Hospital Santiago Apóstol, Vitoria-Gasteiz); Sergio Ros Expósito (Hospital de Viladecans, Barcelona); Ginés Sánchez Nievas, Enrique Júdez Navarro, Manuela Sianes Fernández, María A. García Morales, Isabel Labiano Bastero, Gloria García Consuegra, and Natalia Palmou (Hospital General de Albacete); Silvia Martínez Pardo, Manel Pujol, Elena Riera Alonso, Georgina Salvador (Hospital Mutua Terrassa, Terrassa); Beatriz González Álvarez, Alberto Cantabrana (Hospital Ntra. Sra. de Candelaria, Santa Cruz de Tenerife); Sagrario Bustabad, Esmeralda Delgado (Hospital Univ. de Canarias, La Laguna, Tenerife); Alejandro Muñoz, Sergio

Rodríguez Montero, Luis M. Jiménez (Hospital Univ. de Valme, Sevilla); Javier Rivera Redondo, Teresa González Hernández (Instituto Provincial de Rehabilitación, Madrid); Francisco J. González. Polo (Hospital de Cantoblanco, Madrid); Raúl Menor Almagro (Hospital de Jerez de la Frontera, Jerez de la Frontera, Cádiz); José M. Moreno, Emilio Giner Serret, Carla Lannuzzelli Barroso (Hospital Obispo Polanco, Teruel); Laura Cebrián Méndez, María T. Navío (Hospital Infanta Leonor, Madrid); Cristina Fernández Carballido (Hospital General de Elda, Alicante); Encarnación Pagán, Pablo Mesa del Castillo (Hospital Los Arcos, Murcia); Esperanza Naredo, Ana Cruz (Hospital Severo Ochoa, Madrid); Ana Turrión (Hospital Príncipe de Asturias, Madrid); Julio Sánchez, María Galindo, Javier García González (Hospital Univ. 12 de Octubre, Madrid); Eduardo Collantes, Desireé Ruiz, Pilar Font (Hospital Univ. Reina Sofía, Córdoba); Gema Bonilla (Hospital Univ. La Paz, Madrid); Antonio López Meseguer (Hospital Gutiérrez Ortega, Valdepeñas, Ciudad Real); Manuel J. Moreno, María José Moreno Martínez; María D. Beteta Fernández, Luis F. Linares (Hospital Virgen de la Arrixaca, Murcia); Mercedes Morcillo, María L. González Gómez (Hospital del Escorial, Madrid); Natalia A. Rivera, Olaia Fernández Berrizbeitia, María L. García Vivar (Hospital de Basurto, Bilbao); Manel Riera, Yolanda María León (Hospital Dos de Maig, Barcelona); Joan Maymó, Miriam Amirall, Silvia Iniesta Escolano, Silvia Sánchez Serrano, María P. Lis Bona (Hospital del Mar, Barcelona); Jordi Fiter, Julia Fernández Melón, Luis Espadaler (Hospital Universitario Son Espases, Palma de Mallorca); Olga Maiz, Joaquín Belzunegui, Inmaculada Banegil (Hospital de Donostia, Donostia); César Díaz (Hospital de la Santa Creu i Sant Pau, Barcelona); Ramón Valls (Hospital de Palamós, Gerona); Iván Castellví, María Bonet, Estefanía Moreno Ruzafa (Hospital Comarcal de L'Alt Penedés, Vilafranca del Penedés, Barcelona); Jaime Calvo Alen (Hospital Sierrallana, Torrelavega); Trinidad Pérez Sandoval (Complejo Asistencial de León); Eva Revuelta Evrard (Hospital General de

Ciudad Real); Javier R. Godo, Cruz Fernández Espartero (Hospital General de Móstoles, Madrid); Francisco J. Navarro Blasco, José A. González (Hospital General Universitario de Elche, Alicante); José A. Miranda-Filloy (Hospital Xeral Calde, Lugo).

References

- AVINA-ZUBIETA JA, THOMAS J, SADATSAFAVI M, LEHMAN AJ, LACAILE D: Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. *Ann Rheum Dis* 2012; 71: 1524-9.
- DESSEIN PH, JOFFE BI, VELLER MG *et al.*: Traditional and non-traditional cardiovascular risk factors are associated with atherosclerosis in rheumatoid arthritis. *J Rheumatol* 2005; 32: 435-42.
- GONZALEZ-GAY MA, GONZALEZ-JUANATEY C, LOPEZ-DIAZ MJ *et al.*: HLA-DRB1 and persistent chronic inflammation contribute to cardiovascular events and cardiovascular mortality in patients with rheumatoid arthritis. *Arthritis Rheum* 2007; 57: 125-32.
- CASTAÑEDA S, NURMOHAMED MT, GONZÁLEZ-GAY MA: Cardiovascular disease in inflammatory rheumatic diseases. *Best Pract Res Clin Rheumatol* 2016; 30: 851-69.
- GONZALEZ-GAY MA, GONZALEZ-JUANATEY C, MARTIN J: Rheumatoid arthritis: a disease associated with accelerated atherogenesis. *Semin Arthritis Rheum* 2005; 35: 8-17.
- SODERGREN A, KARP K, BOMAN K *et al.*: Atherosclerosis in early rheumatoid arthritis: very early endothelial activation and rapid progression of intima media thickness. *Arthritis Res Ther* 2010; 12: R158.
- GILES JT, POST WS, BLUMENTHAL RS *et al.*: Longitudinal predictors of progression of carotid atherosclerosis in rheumatoid arthritis. *Arthritis Rheum* 2011; 63: 3216-25.
- LÓPEZ-MEJÍAS R, CASTAÑEDA S, GONZÁLEZ-JUANATEY C *et al.*: Cardiovascular risk assessment in patients with rheumatoid arthritis: The relevance of clinical, genetic and serological markers. *Autoimmun Rev* 2016; 15: 1013-30.
- KITAS GD, GABRIEL SE: Cardiovascular disease in rheumatoid arthritis: state of the art and future perspectives. *Ann Rheum Dis* 2011; 70: 8-14.
- DEL RINCON I, WILLIAMS K, STERN MP, FREEMAN GL, O'LEARY DH, ESCALANTE A: Association between carotid atherosclerosis and markers of inflammation in rheumatoid arthritis patients and healthy subjects. *Arthritis Rheum* 2003; 48: 1833-40.
- MCEWAN P, WILLIAMS JE, GRIFFITHS JD *et al.*: Evaluating the performance of the Framingham risk equations in a population with diabetes. *Diabetes Med* 2004; 21: 318-23.
- ZGIBOR JC, PIATT GA, RUPPERT K, ORCHARD TJ, ROBERTS MS: Deficiencies of cardiovascular risk prediction models for type 1 diabetes. *Diabetes Care* 2006; 29: 1860-5.
- RUPPERT K, ROBERTS MS, ORCHARD TJ, ZGIBOR JC: Cardiovascular disease risk prediction in type 1 diabetes: accounting for the differences. *Diabetes Res Clin Pract* 2007; 78: 234-7.
- SOLOMON DH, KARLSON EW, RIMM EB *et al.*: Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. *Circulation* 2003; 107: 1303-7.
- MEUNE C, TOUZE E, TRINQUART L, ALLANORE Y: Trends in cardiovascular mortality in patients with rheumatoid arthritis over 50 years: a systematic review and meta-analysis of cohort studies. *Rheumatology (Oxford)* 2009; 48: 1309-13.
- GOODSON NJ, WILES NJ, LUNT M, BARRETT EM, SILMAN AJ, SYMMONS DP: Mortality in early inflammatory polyarthritis: cardiovascular mortality is increased in seropositive patients. *Arthritis Rheum* 2002; 46: 2010-9.
- HOURI LEVI E, WATAD A, WHITBY A *et al.*: Coexistence of ischemic heart disease and rheumatoid arthritis patients-A case control study. *Autoimmun Rev* 2016; 15: 393-6.
- PETERS MJ, VAN DER HORST-BRUIJNSMA IE, DIJKMANS BA, NURMOHAMED MT: Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis. *Semin Arthritis Rheum* 2004; 34: 585-92.
- HEENEMAN S, DAEMEN MJ: Cardiovascular risks in spondyloarthritides. *Curr Opin Rheumatol* 2007; 19: 358-62.
- JAMNITSKI A, SYMMONS D, PETERS MJ, SATTAR N, MCINNES I, NURMOHAMED MT: Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review. *Ann Rheum Dis* 2013; 72: 211-6.
- HORREAU C, POULPARD C, BRENAUT E *et al.*: Cardiovascular morbidity and mortality in psoriasis and psoriatic arthritis: a systematic literature review. *J Eur Acad Dermatol Venereol Suppl* 2013; 3: 12-29.
- GLADMAN DD, ANG M, SU L, TOM BD, SCHENTAG CT, FAREWELL VT: Cardiovascular morbidity in psoriatic arthritis. *Ann Rheum Dis* 2009; 68: 1131-5.
- GONZALEZ-JUANATEY C, LLORCA J, MIRANDA-FILLOY JA *et al.*: Endothelial dysfunction in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. *Arthritis Rheum* 2007; 57: 287-93.
- GONZALEZ-JUANATEY C, LLORCA J, AMIGODIAZ E, DIERSSEN T, MARTIN J, GONZALEZ-GAY MA: High prevalence of subclinical atherosclerosis in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. *Arthritis Rheum* 2007; 57: 1074-80.
- LEHTINEN K: Mortality and causes of death in 398 patients admitted to hospital with ankylosing spondylitis. *Ann Rheum Dis* 1993; 52: 174-6.
- MATHIEU S, GOSSEC L, DOUGADOS M, SOUBRIER M: Cardiovascular profile in ankylosing spondylitis: a systematic review and meta-analysis. *Arthritis Care Res (Hoboken)* 2011; 63: 557-63.
- CASTAÑEDA S, MARTIN-MARTINEZ MA, GONZALEZ-JUANATEY C *et al.*: CARMA PROJECT COLLABORATIVE: Cardiovascular morbidity and associated risk factors in Spanish patients with chronic inflammatory rheumatic diseases attending rheumatology clinics: baseline data of the CARMA Project. *Semin Arthritis Rheum* 2015; 44: 618-26.
- ARNETT FC, EDWORTHY SM, BLOCH DA *et al.*: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. *Arthritis Rheum* 1988; 31: 315-24.
- VAN DER LINDEN S, VALKENBURG HA, CATS A: Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. *Arthritis Rheum* 1984; 27: 361-8.
- MOLL JM, WRIGHT V: Psoriatic arthritis. *Semin Arthritis Rheum* 1973; 3: 55-78.
- CONROY RM, PYÖRÄLÄ K, FITZGERALD AP *et al.*: SCORE Project group. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. *Eur Heart J* 2003; 24: 987-1003.
- EUROPEAN ASSOCIATION FOR CARDIOVASCULAR PREVENTION & REHABILITATION, REINER Z, CATAPANO AL, DE BACKER G *et al.*: ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Addenda. Addendum I. *Eur Heart J* 2011; 32: 1769-818.
- DOUGADOS M, SOUBRIER M, ANTUNEZ A *et al.*: Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). *Ann Rheum Dis* 2014; 73: 62-8.
- RUSCITTI P, MARGIOTTA DPE, MACALUSO F *et al.*: Subclinical atherosclerosis and history of cardiovascular events in Italian patients with rheumatoid arthritis: Results from a cross-sectional, multicenter GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale) study. *Medicine (Baltimore)* 2017; 96: e8180.
- MASUDA H, MIYAZAKI T, SHIMADA K *et al.*: Disease duration and severity impacts on long-term cardiovascular events in Japanese patients with rheumatoid arthritis. *J Cardiol* 2014; 64: 366-70.
- MATHIEU S, PEREIRA B, SOUBRIER M: Cardiovascular events in ankylosing spondylitis: an updated meta-analysis. *Semin Arthritis Rheum* 2015; 44: 551-5.
- VINKER SHUSTER M, GENDELMAN O, TIOSANO S, COMANESHTER D, COHEN AD, AMITAL H: Ischemic heart disease and ankylosing spondylitis-assessing the role of inflammation. *Clin Rheumatol* 2018; 37: 1053-8.
- MARTÍN-MARTÍNEZ MA, GONZÁLEZ-JUANATEY C, CASTAÑEDA S *et al.*: Recommendations for the management of cardiovascular risk in patients with rheumatoid arthritis: scientific evidence and expert opinion. *Semin Arthritis Rheum* 2014; 44: 1-8.
- AGCA R, HESLINGA SC, ROLLEFSTAD S *et al.*: EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. *Ann Rheum Dis* 2017; 76: 17-28.
- LOZA E, LAJAS C, ANDREU JL *et al.*: Consensus statement on a framework for the

- management of comorbidity and extra-articular manifestations in rheumatoid arthritis. *Rheumatol Int* 2015; 35: 445-58.
41. CORRALES A, PARRA JA, GONZÁLEZ-JUANATEY C *et al.*: Cardiovascular risk stratification in rheumatic diseases: carotid ultrasound is more sensitive than Coronary Artery Calcification Score to detect subclinical atherosclerosis in patients with rheumatoid arthritis. *Ann Rheum Dis* 2013; 72: 1764-70.
 42. CORRALES A, GONZÁLEZ-JUANATEY C, PEIRÓ ME, BLANCO R, LLORCA J, GONZÁLEZ-GAY MA: Carotid ultrasound is useful for the cardiovascular risk stratification of patients with rheumatoid arthritis: results of a population-based study. *Ann Rheum Dis* 2014; 73: 722-7.
 43. GONZÁLEZ-GAY MA, GONZÁLEZ-JUANATEY C, LLORCA J: Carotid ultrasound in the cardiovascular risk stratification of patients with rheumatoid arthritis: when and for whom? *Ann Rheum Dis* 2012; 71: 796-8.
 44. RUSCITTI P, URSINI F, CIPRIANI P *et al.*: Poor clinical response in rheumatoid arthritis is the main risk factor for diabetes development in the short-term: A 1-year, single-centre, longitudinal study. *PLoS One* 2017; 12: e0181203.
 45. CREPALDI G, SCIRÈ CA, CARRARA G *et al.*: Cardiovascular comorbidities relate more than others with disease activity in rheumatoid arthritis. *PLoS One* 2016; 11: e0146991.
 46. GONZALEZ-JUANATEY C, LLORCA J, GONZALEZ-GAY MA: Correlation between endothelial function and carotid atherosclerosis in rheumatoid arthritis patients with longstanding disease. *Arthritis Res Ther* 2011; 13: 101.
 47. KAO AH, KRISHNASWAMI S, CUNNINGHAM A *et al.*: Subclinical coronary artery calcification and relationship to disease duration in women with rheumatoid arthritis. *J Rheumatol* 2008; 35: 61-9.
 48. GONZALEZ-GAY MA, GONZALEZ-JUANATEY C, PIÑEIRO A, GARCIA-PORRUA C, TESTA A, LLORCA J: High-grade C-reactive protein elevation correlates with accelerated atherogenesis in patients with rheumatoid arthritis. *J Rheumatol* 2005; 32: 1219-23.
 49. VAN DEN HOEK J, ROORDA LD, BOSHIJZEN HC *et al.*: Trend in and predictors for cardiovascular mortality in patients with rheumatoid arthritis over a period of 15 years: a prospective cohort study. *Clin Exp Rheumatol* 2016; 34: 813-9.